Septerna (NASDAQ:SEPN) Stock Price Up 6.4% – Should You Buy?

Shares of Septerna, Inc. (NASDAQ:SEPN) shot up 6.4% on Tuesday . The company traded as high as $23.10 and last traded at $23.07. 84,226 shares changed hands during trading, a decline of 60% from the average session volume of 211,519 shares. The stock had previously closed at $21.69.

Wall Street Analyst Weigh In

A number of research analysts recently commented on SEPN shares. Wells Fargo & Company began coverage on shares of Septerna in a research note on Tuesday, November 19th. They issued an “overweight” rating and a $43.00 price target on the stock. JPMorgan Chase & Co. assumed coverage on shares of Septerna in a research report on Tuesday, November 19th. They set an “overweight” rating and a $38.00 price target on the stock. Cantor Fitzgerald initiated coverage on shares of Septerna in a report on Tuesday, November 19th. They set an “overweight” rating and a $50.00 price target on the stock. Finally, TD Cowen began coverage on Septerna in a report on Tuesday, November 19th. They issued a “buy” rating for the company.

Septerna Price Performance

Insiders Place Their Bets

In other Septerna news, major shareholder Rock Ventures V. L.P. Third bought 370,500 shares of the firm’s stock in a transaction dated Monday, October 28th. The stock was bought at an average cost of $18.00 per share, with a total value of $6,669,000.00. Following the completion of the transaction, the insider now directly owns 6,215,591 shares in the company, valued at approximately $111,880,638. The trade was a 6.34 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.